[MO38] Mini-Oral Session 38　臓器横断プログラム4（第一相試験と遺伝子異常に基づく医療）
【E】

[MO38-1] Phase I study of BI 836880 alone or combined with ezabenlimab in Japanese patients (pts) with advanced solid tumors

^○Kentaro Yamazaki¹, Takafumi Koyama², Toshio Shimizu², Akiko Todaka¹, Takeshi Kawakami¹, Jangsoo Yoon³, Damijan Erzen⁴, Jianrui Hou³, Noboru Yamamoto² (1.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 2.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, 3.Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan, 4.Boehringer Ingelheim GmbH, Ingelheim, Germany)